1. Home
  2. HRL vs BBIO Comparison

HRL vs BBIO Comparison

Compare HRL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hormel Foods Corporation

HRL

Hormel Foods Corporation

HOLD

Current Price

$23.69

Market Cap

13.0B

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$75.72

Market Cap

14.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRL
BBIO
Founded
1891
2015
Country
United States
United States
Employees
20000
N/A
Industry
Meat/Poultry/Fish
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.0B
14.4B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
HRL
BBIO
Price
$23.69
$75.72
Analyst Decision
Buy
Strong Buy
Analyst Count
6
21
Target Price
$28.00
$76.24
AVG Volume (30 Days)
6.0M
2.1M
Earning Date
12-04-2025
10-29-2025
Dividend Yield
4.94%
N/A
EPS Growth
N/A
N/A
EPS
0.87
N/A
Revenue
$12,106,160,000.00
$353,780,000.00
Revenue This Year
$3.46
$128.44
Revenue Next Year
$2.75
$76.14
P/E Ratio
$27.23
N/A
Revenue Growth
1.55
62.46
52 Week Low
$21.03
$25.34
52 Week High
$32.07
$77.20

Technical Indicators

Market Signals
Indicator
HRL
BBIO
Relative Strength Index (RSI) 53.29 65.34
Support Level $23.65 $73.48
Resistance Level $24.21 $76.51
Average True Range (ATR) 0.51 2.49
MACD 0.02 -0.27
Stochastic Oscillator 34.42 78.39

Price Performance

Historical Comparison
HRL
BBIO

About HRL Hormel Foods Corporation

Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and became a branded food company. The firm sells its wares through multiple channels, including US retail (61.6% of fiscal 2025 sales), US foodservice (32.6%), and international (5.9%). By product, 73% of fiscal 2025 sales were from perishable food and 27% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: